India Pharma Outlook Team | Friday, 26 September 2025
Sandoz, a global leader in the supply of affordable medicines, announced the US market release of its generic iron sucrose injection, following the US Food and Drug Administration (FDA) approval made recently. The product can now be transported to any point of the entire country, thus broadening the US iron therapy portfolio of Sandoz.
Iron deficiency anemia (IDA) is primarily treated with intravenous iron sucrose, which is the most frequently used method in the US. The disease affects almost 5 million people in the U.S., including the patients with chronic kidney disease (CKD stages 3–5). CKD is responsible for almost 19 million people that can develop anemia in the US.
The treatment is done in dialysis centers and healthcare facilities. In fact, iron sucrose is used to replenish iron stores, to promote the production of red blood cells, and to solve the most severe iron deficiencies if oral supplements are ineffective. The production of this formulation is authorized for all the specifications of the reference product, Venofer.
Also Read: Organon Backs Women Repro Health on Contraception Day
Keren Haruvi, President, Sandoz North America said, "By offering this alternative to iron sucrose, we emphasize the fact that our concern is to provide patients with reliable and affordable medicines, especially in the case of chronic diseases." "Our high-quality product is the one that best fits the needs of the patients, clinicians, and healthcare providers throughout the US," she added.
Anemia due to iron deficiency is a condition in which the body lacks iron required for the production of healthy red blood cells, with oxygen transport being the most affected besides immunity and general wellness. Iron deficiency conditions become chronic and complicated as in renal patients, hence the necessity of iron therapy.
